Another one (NCT04020575) focuses on HER2+ breast cancer patients with MUC1-positive tumors and advanced disease and studies the administration of a CAR-T cell (huMNC2-CAR44) that targets the extracellular domain of the cleaved form of MUC1 (called MUC1*), which is the isoform that acts as a growth factor receptor and is present on a large percentage of solid tumors, including breast tumors [307]. Here, MUC1 is linked to breast carcinoma.